Pelthos Therapeutics (NYSEAMERICAN:PTHS) Releases Quarterly Earnings Results

Pelthos Therapeutics (NYSEAMERICAN:PTHS) posted its earnings results on Thursday. The company reported ($6.62) earnings per share for the quarter, FiscalAI reports. The company had revenue of $15.60 million for the quarter.

Here are the key takeaways from Pelthos Therapeutics’ conference call:

• ZELSUVMI revenue and prescriptions grew strongly: Q2 net product revenue rose 45% sequentially to $15.4 million, while prescribed units increased 48% to 11,925. The company reported more than 25,000 patients prescribed and over 8,000 unique HCP prescribers since launch.
• Market access and commercial execution continue to support demand. Commercial insurance coverage reached 59% and Medicaid coverage 100%, while the 67-territory sales force, PBM contracting, and a recent expert-consensus publication are expected to aid further adoption.
• Pelthos reiterated plans to launch the complementary products XEPI in the first quarter of 2027 and XEGLYZE in the third quarter of 2027. Management expects to leverage its existing sales infrastructure, limiting incremental commercial overhead.
• The company restated its first-quarter 2026 financial statements because of an error in fair-value accounting for related-party convertible debt. Management said the adjustment does not affect cash, revenue, operating expenses, operating loss, or cash flows, but the restatement adds financial-reporting risk.
• Pelthos remains loss-making and faces near-term cost pressure: Q2 net loss was $23.4 million, cash was $24.2 million, and an out-of-specification API issue caused a $0.9 million inventory write-off. Gross-to-net deductions are expected to rise from 29.6% toward the low-to-mid-30% range, or potentially higher if another payer contract is added.

Pelthos Therapeutics Trading Down 3.3%

Shares of Pelthos Therapeutics stock traded down $0.96 during trading on Friday, hitting $27.99. The stock had a trading volume of 11,462 shares, compared to its average volume of 27,794. Pelthos Therapeutics has a 12 month low of $18.19 and a 12 month high of $37.50. The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. The firm’s fifty day simple moving average is $27.45 and its 200-day simple moving average is $25.12. The stock has a market cap of $97.41 million, a PE ratio of -1.36 and a beta of 3.10.

Analysts Set New Price Targets

Separately, Oppenheimer restated an “outperform” rating and issued a $64.00 target price on shares of Pelthos Therapeutics in a report on Friday. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Pelthos Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.40.

Insiders Place Their Bets

In other news, Director Todd C. Davis acquired 35,948 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $27.82 per share, with a total value of $1,000,073.36. Following the completion of the purchase, the director directly owned 75,834 shares in the company, valued at approximately $2,109,701.88. This trade represents a 90.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 1,638 shares of company stock valued at $43,107. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in PTHS. Persistent Asset Partners Ltd lifted its holdings in Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares in the last quarter. Pale Fire Capital SE raised its position in Pelthos Therapeutics by 59.5% during the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after purchasing an additional 4,819 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter worth $343,000. Geode Capital Management LLC grew its position in shares of Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after buying an additional 3,295 shares in the last quarter. Finally, Knott David M Jr raised its holdings in shares of Pelthos Therapeutics by 9.3% in the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock valued at $443,000 after acquiring an additional 1,792 shares in the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).